poster

Late-Onset Agitated Depression with Anxious and Obsessive Features Triggered by Parental Decline: A Case for Integrated Pharmacology, Neuromodulation, and Psychodynamic Treatments

A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...

10/17/2025

Pilot Implementation Of Mindfulness Meditation With Esketamine For Major Depressive Disorder

This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...

10/17/2025

Retrospective Analysis of Real-World Transition Strategies for Xanomeline and Trospium Chloride in Adult Patients With Schizophrenia

Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...

10/17/2025

Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Bipolar I Disorder

This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...

10/17/2025

Results From a Phase 4, Open-Label, Multicenter, Two-Cohort, Two-Period, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia

Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...

10/17/2025

Long-Term Effectiveness With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Results From up to 48 Weeks Open Label Treatment in the Phase 3 SOLARIS Trial

TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...

10/17/2025

Residual Symptom Burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From The CRESCENDO Survey

CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...

10/17/2025

Improvement in Bothersome Mood, Cognitive, and Functional Impacts of Idiopathic Hypersomnia After Low-Sodium Oxybate Treatment in the DUET Study

Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...

10/17/2025

Neuropsychiatric and Cognitive Sequelae of Severe Hypothyroidism: Insights into Endocrine–Brain Interactions

Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...

10/17/2025

Lumateperone for the Prevention of Relapse in Patients with Schizophrenia:" Results from a double-blind, placebo-controlled, randomized withdrawal, phase 3 trial

Short Description: This Phase 3, double-blind, randomized study (NCT04959032) investigated the efficacy and safety of lumateperone 42 mg for relapse prevention in adult patients with schi...

10/17/2025

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia-Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.